array:24 [
  "pii" => "S0001731023005057"
  "issn" => "00017310"
  "doi" => "10.1016/j.ad.2022.08.034"
  "estado" => "S300"
  "fechaPublicacion" => "2023-10-01"
  "aid" => "3562"
  "copyright" => "AEDV"
  "copyrightAnyo" => "2023"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "sco"
  "cita" => "Actas Dermosifiliogr. 2023;114:812-5"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S0001731023006233"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2022.08.036"
    "estado" => "S300"
    "fechaPublicacion" => "2023-10-01"
    "aid" => "3614"
    "copyright" => "AEDV"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "sco"
    "cita" => "Actas Dermosifiliogr. 2023;114:T812-T815"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Resident&#39;s Forum</span>"
      "titulo" => " RF &#8211; Bicalutamide&#58; An Emergent Treatment Option in Trichology"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "T812"
          "paginaFinal" => "T815"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "FR &#8211; Bicalutamida&#44; una realidad emergente en tricolog&#237;a"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "M&#46;D&#46; Pegalajar-Garc&#237;a, A&#46; Gil-Villalba, F&#46;J&#46; de la Torre-Gomar"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "M&#46;D&#46;"
              "apellidos" => "Pegalajar-Garc&#237;a"
            ]
            1 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Gil-Villalba"
            ]
            2 => array:2 [
              "nombre" => "F&#46;J&#46;"
              "apellidos" => "de la Torre-Gomar"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023006233?idApp=UINPBA000044"
    "url" => "/00017310/0000011400000009/v1_202310020456/S0001731023006233/v1_202310020456/en/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S0001731023006245"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2023.07.016"
    "estado" => "S300"
    "fechaPublicacion" => "2023-10-01"
    "aid" => "3615"
    "copyright" => "AEDV"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "pgl"
    "cita" => "Actas Dermosifiliogr. 2023;114:T802-T811"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Consensus Document</span>"
      "titulo" => " Moderate to Severe Psoriasis in Older Adults&#58; Recommendations on Management From the Psoriasis Working Group of the Spanish Academy of Dermatology and Venereology &#40;AEDV&#41;"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "T802"
          "paginaFinal" => "T811"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Recomendaciones del Grupo de Psoriasis de la Academia Espa&#241;ola de Dermatolog&#237;a y Venereolog&#237;a sobre el manejo del paciente de edad avanzada con psoriasis en placas moderada-grave"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "J&#46; Mataix, L&#46; Garc&#237;a, I&#46; Belinch&#243;n, J&#46;C&#46; Ruiz Carrascosa, P&#46; de la Cueva, J&#46;M&#46; Carrascosa"
          "autores" => array:6 [
            0 => array:2 [
              "nombre" => "J&#46;"
              "apellidos" => "Mataix"
            ]
            1 => array:2 [
              "nombre" => "L&#46;"
              "apellidos" => "Garc&#237;a"
            ]
            2 => array:2 [
              "nombre" => "I&#46;"
              "apellidos" => "Belinch&#243;n"
            ]
            3 => array:2 [
              "nombre" => "J&#46;C&#46;"
              "apellidos" => "Ruiz Carrascosa"
            ]
            4 => array:2 [
              "nombre" => "P&#46;"
              "apellidos" => "de la Cueva"
            ]
            5 => array:2 [
              "nombre" => "J&#46;M&#46;"
              "apellidos" => "Carrascosa"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023006245?idApp=UINPBA000044"
    "url" => "/00017310/0000011400000009/v1_202310020456/S0001731023006245/v1_202310020456/en/main.assets"
  ]
  "asociados" => array:1 [
    0 => array:18 [
      "pii" => "S0001731023006233"
      "issn" => "00017310"
      "doi" => "10.1016/j.ad.2022.08.036"
      "estado" => "S300"
      "fechaPublicacion" => "2023-10-01"
      "aid" => "3614"
      "copyright" => "AEDV"
      "documento" => "article"
      "crossmark" => 1
      "subdocumento" => "sco"
      "cita" => "Actas Dermosifiliogr. 2023;114:T812-T815"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:1 [
        "total" => 0
      ]
      "en" => array:10 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Resident&#39;s Forum</span>"
        "titulo" => " RF &#8211; Bicalutamide&#58; An Emergent Treatment Option in Trichology"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "T812"
            "paginaFinal" => "T815"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "es" => array:1 [
            "titulo" => "FR &#8211; Bicalutamida&#44; una realidad emergente en tricolog&#237;a"
          ]
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "M&#46;D&#46; Pegalajar-Garc&#237;a, A&#46; Gil-Villalba, F&#46;J&#46; de la Torre-Gomar"
            "autores" => array:3 [
              0 => array:2 [
                "nombre" => "M&#46;D&#46;"
                "apellidos" => "Pegalajar-Garc&#237;a"
              ]
              1 => array:2 [
                "nombre" => "A&#46;"
                "apellidos" => "Gil-Villalba"
              ]
              2 => array:2 [
                "nombre" => "F&#46;J&#46;"
                "apellidos" => "de la Torre-Gomar"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023006233?idApp=UINPBA000044"
      "url" => "/00017310/0000011400000009/v1_202310020456/S0001731023006233/v1_202310020456/en/main.assets"
    ]
  ]
  "es" => array:13 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Foro de Residentes</span>"
    "titulo" => "FR - Bicalutamida&#44; una realidad emergente en tricolog&#237;a"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "812"
        "paginaFinal" => "815"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "M&#46;D&#46; Pegalajar- Garc&#237;a, A&#46; Gil-Villalba, F&#46;J&#46; de la Torre-Gomar"
        "autores" => array:3 [
          0 => array:2 [
            "nombre" => "M&#46;D&#46;"
            "apellidos" => "Pegalajar- Garc&#237;a"
          ]
          1 => array:2 [
            "nombre" => "A&#46;"
            "apellidos" => "Gil-Villalba"
          ]
          2 => array:4 [
            "nombre" => "F&#46;J&#46;"
            "apellidos" => "de la Torre-Gomar"
            "email" => array:1 [
              0 => "fjtogo@gmail.com"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:2 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Hospital Cl&#237;nico Universitario San Cecilio&#44; Granada&#44; Espa&#241;a"
            "identificador" => "aff0005"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Autor para correspondencia&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "en" => array:1 [
        "titulo" => "RF - Bicalutamide&#58; An Emergent Treatment Option in Trichology"
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">La bicalutamida&#44; un antagonista no esteroideo del receptor de andr&#243;genos aprobado para el tratamiento del c&#225;ncer de pr&#243;stata&#44; se ha posicionado recientemente como una alternativa terap&#233;utica en tricolog&#237;a&#46; Se usa fuera de ficha t&#233;cnica para pacientes con una alopecia androgen&#233;tica de patr&#243;n femenino &#40;AAPF&#41;<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">1</span></a>&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">El mecanismo de acci&#243;n de la bicalutamida es selectivo a nivel perif&#233;rico en las c&#233;lulas foliculares de la papila d&#233;rmica&#46; Con las dosis empleadas en tricolog&#237;a&#44; no presenta actividad mineral ni glucocorticoide&#44; ni ha mostrado efectos en los niveles de testosterona&#44; estr&#243;genos o progest&#225;genos<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a>&#46;</p><p id="par0015" class="elsevierStylePara elsevierViewall">No hay un consenso acerca de cu&#225;l es la dosis adecuada de bicalutamida para la AAPF&#44; aunque&#44; en cualquier caso&#44; siempre es inferior a la aprobada para el c&#225;ncer de pr&#243;stata&#46; En la serie m&#225;s numerosa&#44; la de Ismail et al&#46;<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a>&#44; la dosis m&#225;s utilizada fue de 10<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#237;a&#44; mientras que en la Fern&#225;ndez-Nieto et al&#46;<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">1</span></a> fue entre 25 y 50<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#237;a&#46; En ambos se administr&#243; generalmente combinada con otros f&#225;rmacos&#44; principalmente con minoxidil oral a dosis de 0&#44;5-1<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#237;a&#44; y&#44; en menor medida&#44; con espironolactona<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">1&#44;2</span></a>&#46; El tiempo transcurrido hasta la mejor&#237;a vari&#243; entre los 6 meses y los 2 a&#241;os&#44; encontr&#225;ndose una mejor&#237;a a los 6 meses de un 20&#44;2 a un 27&#44;5&#37; en la escala de Sinclair<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">1&#44;2</span></a> &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">tabla 1</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0020" class="elsevierStylePara elsevierViewall">Dada su actividad antiandrog&#233;nica&#44; algunos estudios sugieren que su empleo a una dosis media de 14&#44;4<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#237;a concomitante con minoxidil oral a una dosis media de 1&#44;5<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#237;a durante m&#225;s de 3 meses&#44; podr&#237;a reducir la hipertricosis secundaria a este&#44; lo que permitir&#237;a obtener una mejor tolerancia a dosis altas de minoxidil y&#44; as&#237;&#44; optimizar el tratamiento de la AAPF<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">3</span></a>&#46;</p><p id="par0025" class="elsevierStylePara elsevierViewall">Debido a su papel sobre la miniaturizaci&#243;n del fol&#237;culo&#44; y teniendo en cuenta el efecto anterior&#44; se utiliz&#243; con &#233;xito en una paciente con alopecia central centr&#237;fuga con una dosis de 10<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#237;a&#44; en combinaci&#243;n con 0&#44;45<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#237;a de minoxidil oral y un corticoide t&#243;pico<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">4</span></a>&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">En los estudios publicados ha presentado un buen perfil de seguridad y tolerabilidad<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">1&#8211;3</span></a>&#46; El efecto secundario m&#225;s referido fue la hepatotoxicidad&#44; encontr&#225;ndose hipertransaminasemia en el 2&#44;9-12&#44;5&#37;&#44; en todos los casos con un valor inferior a 3 veces el l&#237;mite superior de normalidad<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">5</span></a>&#46; Este efecto ser&#237;a dosis dependiente&#44; mejorando la mayor&#237;a de los casos de forma espont&#225;nea o tras disminuir la dosis de bicalutamida&#44; sin requerir su suspensi&#243;n<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a>&#46; Otros efectos indeseables menos frecuentes fueron alteraciones gastrointestinales&#44; edema de miembros&#44; mastalgia o migra&#241;a&#44; entre otros &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">tabla 1</a>&#41;<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">1&#8211;3</span></a>&#46;</p><p id="par0035" class="elsevierStylePara elsevierViewall">La bicalutamida est&#225; contraindicada en mujeres embarazadas y se recomienda administrarla con precauci&#243;n en mujeres con una historia personal o familiar de tumores hormono-dependientes<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">5</span></a>&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">Dada la evidencia actual&#44; se ha propuesto realizar previo a su inicio una anal&#237;tica sangu&#237;nea que incluya hemograma&#44; creatinina&#44; enzimas hep&#225;ticas&#44; perfil lip&#237;dico y tiempo de protrombina&#46; Esta se debe repetir durante el seguimiento cada 3-6 meses<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">2&#44;5</span></a>&#46;</p><p id="par0045" class="elsevierStylePara elsevierViewall">En los &#250;ltimos a&#241;os&#44; los avances en el conocimiento de la bicalutamida han permitido valorarla como una importante alternativa en el tratamiento de AAPF&#44; sobre todo en las pacientes premenop&#225;usicas con otros rasgos de hiperandrogenismo como acn&#233;&#44; hirsutismo o seborrea<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">1</span></a>&#46; Aunque se requiere una mayor evidencia que corrobore su eficacia&#44; seguridad y estandaricen su posolog&#237;a y seguimiento&#44; parece que su uso a una dosis de 10-50<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#237;a es eficaz y seguro en monoterapia o en combinaci&#243;n con otros f&#225;rmacos&#46;</p></span>"
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:1 [
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec1702476"
          "palabras" => array:4 [
            0 => "Alopecia androgen&#233;tica"
            1 => "Bicalutamida"
            2 => "Minoxidil"
            3 => "Hipertricosis"
          ]
        ]
      ]
    ]
    "multimedia" => array:1 [
      0 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Tabla 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Autor&#237;a del estudio&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Tipo de estudio&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Patolog&#237;a tratada&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N&#46;<span class="elsevierStyleSup">o</span> pacientes tratados&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Posolog&#237;a&#40;mg&#47;d&#237;a&#41;&#91;&#37; pacientes tratados&#93;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">F&#225;rmacos concomitantes&#40;&#37; pacientes tratados&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Duraci&#243;n del tratamiento&#40;meses&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Tiempo inicial de mejor&#237;a medido&#40;meses&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Resultados a los 6 meses&#40;reducci&#243;n escala de Sinclair&#44; &#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Efectos secundarios&#40;&#37; pacientes afectos&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N&#46;<span class="elsevierStyleSup">o</span> abandonos terap&#233;uticos por efectos secundarios&#40;&#37; de abandonos&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ismail et al&#46;<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Serie de casos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">AAPF&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">316&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-10 &#91;69&#44;6&#37;&#93;-12&#44;5 &#91;2&#44;5&#37;&#93;-20 &#91;25&#37;&#93;-25 &#91;1&#37;&#125;-30 &#91;1&#46;6&#37;&#93;-50 &#91;0&#44;3&#37;&#93;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-Minoxidil oral<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> &#40;97&#44;4&#37;&#41;-Espironolactona<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a>&#40;54&#44;4&#37;&#41;-Monoterapia &#40;1&#44;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2-69&#40;6&#44;21 de media&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">20&#44;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-Hipertransaminasemia &#40;2&#44;9&#37;&#41;-Edema en miembros &#40;2&#44;5&#37;&#41;-Alteraciones gastrointestinales &#40;1&#44;9&#37;&#41;-En<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>1&#37; de los casos&#44; respectivamente&#58; mastalgia&#44; erupci&#243;n acneiforme&#44; astenia&#44; mialgias&#44; disminuci&#243;n de la libido&#44; alteraciones menstruales&#44; cambios de humor&#44; palpitaciones y disnea&#44; fotosensibilidad&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">13&#40;4&#44;1&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Fern&#225;ndez-Nieto et al&#46;<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">1</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Serie de casos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">AAPF&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">44&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-25 &#91;34&#44;1&#37;&#93;-50 &#91;65&#44;9&#37;&#93;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-Minoxidil oral 0&#44;5-1<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#237;a &#40;75&#44;0&#37;&#41;-Dutasteride oral 0&#44;5<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#237;a &#40;15&#44;9&#37;&#41;-Dutasteride en mesoterapia &#40;13&#44;6&#37;&#41;- Minoxidil t&#243;pico 5&#37; &#40;11&#44;4&#37;&#41;-Monoterapia &#40;6&#44;8&#37;&#41;-Finasteride oral 2&#44;5mg&#47;d&#237;a &#40;2&#44;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2-24&#40;10&#44;5 de media&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">27&#44;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-Hipertransaminasemia &#40;11&#44;4&#37;&#41;-Efluvio &#40;6&#44;8&#37;&#41;-Alteraciones menstruales &#40;4&#44;5&#37;&#41;-Migra&#241;a &#40;2&#44;2&#37;&#41;-Hiperplasia endometrial &#40;2&#44;2&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Moussa et al&#46;<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">3</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Serie de casos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hipertricosis secundaria a minoxidil en AAPF&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">35&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-10 &#91;57&#37;&#93;-20 &#91;40&#37;&#93;-25 &#91;3&#37;&#93;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-Minoxidil oral 0&#44;25-10<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#237;a &#91;dosis media de 1&#44;5<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#237;a&#93;&#40;100&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">28&#44;9&#40;25&#44;92 de media&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#44;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">19&#44;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-Hipertransaminasemia &#40;6&#37;&#41;-Disestesia del cuero cabelludo &#40;3&#37;&#41;-Migra&#241;a &#40;3&#37;&#41;-Edema periocular &#40;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#40;5&#44;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Lobon et al&#46;<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">4</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Caso cl&#237;nico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Alopecia central centr&#237;fuga&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">10&#44; con incremento a 20 &#91;100&#37;&#93;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-Minoxidil oral 0&#44;45<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#237;a y dipropionato de clobetasol 0&#44;05&#37; t&#243;pico&#40;100&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3295016.png"
              ]
            ]
          ]
          "notaPie" => array:2 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Dosis de minoxidil oral no especificada&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "b"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Dosis de espironolactona no especificada&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Resumen de la literatura actual acerca del empleo de bicalutamida en tricolog&#237;a</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliograf&#237;a"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:5 [
            0 => array:3 [
              "identificador" => "bib0030"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bicalutamide&#58; A potential new oral antiandrogenic drug for female pattern hair loss"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "D&#46; Fernandez-Nieto"
                            1 => "D&#46; Saceda-Corralo"
                            2 => "J&#46; Jimenez-Cauhe"
                            3 => "O&#46;M&#46; Moreno-Arrones"
                            4 => "R&#46; Rodrigues-Barata"
                            5 => "A&#46; Hermosa-Gelbard"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2020.04.0544"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol &#91;Internet&#93;&#46;"
                        "fecha" => "2020"
                        "volumen" => "83"
                        "paginaInicial" => "e355"
                        "paginaFinal" => "e356"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32320770"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0035"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Safety of oral bicalutamide in female pattern hair loss&#58; A retrospective review of 316 patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "F&#46;F&#46; Ismail"
                            1 => "N&#46; Meah"
                            2 => "L&#46; Trindade de Carvalho"
                            3 => "B&#46; Bhoyrul"
                            4 => "D&#46; Wall"
                            5 => "R&#46; Sinclair"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2020.03.034"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol &#91;Internet&#93;&#46;"
                        "fecha" => "2020"
                        "volumen" => "83"
                        "paginaInicial" => "1478"
                        "paginaFinal" => "1479"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32213304"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bicalutamide improves minoxidil-induced hypertrichosis in female pattern hair loss&#58; A retrospective review of 35 patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "A&#46; Moussa"
                            1 => "A&#46; Kazmi"
                            2 => "L&#46; Bokhari"
                            3 => "R&#46;D&#46; Sinclair"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2021.10.0485"
                      "Revista" => array:2 [
                        "tituloSerie" => "J Am Acad Dermatol &#91;Internet&#93;&#46;"
                        "fecha" => "2021"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0045"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Significant hair regrowth in a Middle Eastern woman with central centrifugal cicatricial alopecia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "K&#46; Lobon"
                            1 => "J&#46; Pinczewski"
                            2 => "B&#46; Bhoyrul"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/ced.14822"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Exp Dermatol &#91;Internet&#93;&#46;"
                        "fecha" => "2022"
                        "volumen" => "47"
                        "paginaInicial" => "136"
                        "paginaFinal" => "138"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34192377"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bicalutamide and the new perspectives for female pattern hair loss treatment&#58; What dermatologists should know"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46;M&#46; Carvalho"
                            1 => "L&#46;D&#46;N&#46; Santos"
                            2 => "P&#46;M&#46; Ramos"
                            3 => "C&#46;J&#46; Machado"
                            4 => "P&#46; Acioly"
                            5 => "S&#46;C&#46; Frattini"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jocd.14773"
                      "Revista" => array:3 [
                        "tituloSerie" => "J Cosmet Dermatol &#91;Internet&#93;&#46;"
                        "fecha" => "2022"
                        "itemHostRev" => array:3 [
                          "pii" => "S0002939420302890"
                          "estado" => "S300"
                          "issn" => "00029394"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "es"
  "url" => "/00017310/0000011400000009/v1_202310020456/S0001731023005057/v1_202310020456/es/main.assets"
  "Apartado" => array:4 [
    "identificador" => "34907"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Foro de Residentes"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/00017310/0000011400000009/v1_202310020456/S0001731023005057/v1_202310020456/es/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023005057?idApp=UINPBA000044"
]
Compartir
Información de la revista

Estadísticas

Siga este enlace para acceder al texto completo del artículo

Foro de Residentes
FR - Bicalutamida, una realidad emergente en tricología
RF - Bicalutamide: An Emergent Treatment Option in Trichology
M.D. Pegalajar- García, A. Gil-Villalba, F.J. de la Torre-Gomar
Autor para correspondencia
fjtogo@gmail.com

Autor para correspondencia.
Servicio de Dermatología, Hospital Clínico Universitario San Cecilio, Granada, España
Leído
13219
Veces
se ha leído el artículo
1931
Total PDF
11288
Total HTML
Compartir estadísticas
 array:24 [
  "pii" => "S0001731023005057"
  "issn" => "00017310"
  "doi" => "10.1016/j.ad.2022.08.034"
  "estado" => "S300"
  "fechaPublicacion" => "2023-10-01"
  "aid" => "3562"
  "copyright" => "AEDV"
  "copyrightAnyo" => "2023"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "sco"
  "cita" => "Actas Dermosifiliogr. 2023;114:812-5"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S0001731023006233"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2022.08.036"
    "estado" => "S300"
    "fechaPublicacion" => "2023-10-01"
    "aid" => "3614"
    "copyright" => "AEDV"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "sco"
    "cita" => "Actas Dermosifiliogr. 2023;114:T812-T815"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Resident&#39;s Forum</span>"
      "titulo" => " RF &#8211; Bicalutamide&#58; An Emergent Treatment Option in Trichology"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "T812"
          "paginaFinal" => "T815"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "FR &#8211; Bicalutamida&#44; una realidad emergente en tricolog&#237;a"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "M&#46;D&#46; Pegalajar-Garc&#237;a, A&#46; Gil-Villalba, F&#46;J&#46; de la Torre-Gomar"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "M&#46;D&#46;"
              "apellidos" => "Pegalajar-Garc&#237;a"
            ]
            1 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Gil-Villalba"
            ]
            2 => array:2 [
              "nombre" => "F&#46;J&#46;"
              "apellidos" => "de la Torre-Gomar"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023006233?idApp=UINPBA000044"
    "url" => "/00017310/0000011400000009/v1_202310020456/S0001731023006233/v1_202310020456/en/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S0001731023006245"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2023.07.016"
    "estado" => "S300"
    "fechaPublicacion" => "2023-10-01"
    "aid" => "3615"
    "copyright" => "AEDV"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "pgl"
    "cita" => "Actas Dermosifiliogr. 2023;114:T802-T811"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Consensus Document</span>"
      "titulo" => " Moderate to Severe Psoriasis in Older Adults&#58; Recommendations on Management From the Psoriasis Working Group of the Spanish Academy of Dermatology and Venereology &#40;AEDV&#41;"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "T802"
          "paginaFinal" => "T811"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Recomendaciones del Grupo de Psoriasis de la Academia Espa&#241;ola de Dermatolog&#237;a y Venereolog&#237;a sobre el manejo del paciente de edad avanzada con psoriasis en placas moderada-grave"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "J&#46; Mataix, L&#46; Garc&#237;a, I&#46; Belinch&#243;n, J&#46;C&#46; Ruiz Carrascosa, P&#46; de la Cueva, J&#46;M&#46; Carrascosa"
          "autores" => array:6 [
            0 => array:2 [
              "nombre" => "J&#46;"
              "apellidos" => "Mataix"
            ]
            1 => array:2 [
              "nombre" => "L&#46;"
              "apellidos" => "Garc&#237;a"
            ]
            2 => array:2 [
              "nombre" => "I&#46;"
              "apellidos" => "Belinch&#243;n"
            ]
            3 => array:2 [
              "nombre" => "J&#46;C&#46;"
              "apellidos" => "Ruiz Carrascosa"
            ]
            4 => array:2 [
              "nombre" => "P&#46;"
              "apellidos" => "de la Cueva"
            ]
            5 => array:2 [
              "nombre" => "J&#46;M&#46;"
              "apellidos" => "Carrascosa"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023006245?idApp=UINPBA000044"
    "url" => "/00017310/0000011400000009/v1_202310020456/S0001731023006245/v1_202310020456/en/main.assets"
  ]
  "asociados" => array:1 [
    0 => array:18 [
      "pii" => "S0001731023006233"
      "issn" => "00017310"
      "doi" => "10.1016/j.ad.2022.08.036"
      "estado" => "S300"
      "fechaPublicacion" => "2023-10-01"
      "aid" => "3614"
      "copyright" => "AEDV"
      "documento" => "article"
      "crossmark" => 1
      "subdocumento" => "sco"
      "cita" => "Actas Dermosifiliogr. 2023;114:T812-T815"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:1 [
        "total" => 0
      ]
      "en" => array:10 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Resident&#39;s Forum</span>"
        "titulo" => " RF &#8211; Bicalutamide&#58; An Emergent Treatment Option in Trichology"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "T812"
            "paginaFinal" => "T815"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "es" => array:1 [
            "titulo" => "FR &#8211; Bicalutamida&#44; una realidad emergente en tricolog&#237;a"
          ]
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "M&#46;D&#46; Pegalajar-Garc&#237;a, A&#46; Gil-Villalba, F&#46;J&#46; de la Torre-Gomar"
            "autores" => array:3 [
              0 => array:2 [
                "nombre" => "M&#46;D&#46;"
                "apellidos" => "Pegalajar-Garc&#237;a"
              ]
              1 => array:2 [
                "nombre" => "A&#46;"
                "apellidos" => "Gil-Villalba"
              ]
              2 => array:2 [
                "nombre" => "F&#46;J&#46;"
                "apellidos" => "de la Torre-Gomar"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023006233?idApp=UINPBA000044"
      "url" => "/00017310/0000011400000009/v1_202310020456/S0001731023006233/v1_202310020456/en/main.assets"
    ]
  ]
  "es" => array:13 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Foro de Residentes</span>"
    "titulo" => "FR - Bicalutamida&#44; una realidad emergente en tricolog&#237;a"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "812"
        "paginaFinal" => "815"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "M&#46;D&#46; Pegalajar- Garc&#237;a, A&#46; Gil-Villalba, F&#46;J&#46; de la Torre-Gomar"
        "autores" => array:3 [
          0 => array:2 [
            "nombre" => "M&#46;D&#46;"
            "apellidos" => "Pegalajar- Garc&#237;a"
          ]
          1 => array:2 [
            "nombre" => "A&#46;"
            "apellidos" => "Gil-Villalba"
          ]
          2 => array:4 [
            "nombre" => "F&#46;J&#46;"
            "apellidos" => "de la Torre-Gomar"
            "email" => array:1 [
              0 => "fjtogo@gmail.com"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:2 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Hospital Cl&#237;nico Universitario San Cecilio&#44; Granada&#44; Espa&#241;a"
            "identificador" => "aff0005"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Autor para correspondencia&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "en" => array:1 [
        "titulo" => "RF - Bicalutamide&#58; An Emergent Treatment Option in Trichology"
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">La bicalutamida&#44; un antagonista no esteroideo del receptor de andr&#243;genos aprobado para el tratamiento del c&#225;ncer de pr&#243;stata&#44; se ha posicionado recientemente como una alternativa terap&#233;utica en tricolog&#237;a&#46; Se usa fuera de ficha t&#233;cnica para pacientes con una alopecia androgen&#233;tica de patr&#243;n femenino &#40;AAPF&#41;<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">1</span></a>&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">El mecanismo de acci&#243;n de la bicalutamida es selectivo a nivel perif&#233;rico en las c&#233;lulas foliculares de la papila d&#233;rmica&#46; Con las dosis empleadas en tricolog&#237;a&#44; no presenta actividad mineral ni glucocorticoide&#44; ni ha mostrado efectos en los niveles de testosterona&#44; estr&#243;genos o progest&#225;genos<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a>&#46;</p><p id="par0015" class="elsevierStylePara elsevierViewall">No hay un consenso acerca de cu&#225;l es la dosis adecuada de bicalutamida para la AAPF&#44; aunque&#44; en cualquier caso&#44; siempre es inferior a la aprobada para el c&#225;ncer de pr&#243;stata&#46; En la serie m&#225;s numerosa&#44; la de Ismail et al&#46;<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a>&#44; la dosis m&#225;s utilizada fue de 10<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#237;a&#44; mientras que en la Fern&#225;ndez-Nieto et al&#46;<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">1</span></a> fue entre 25 y 50<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#237;a&#46; En ambos se administr&#243; generalmente combinada con otros f&#225;rmacos&#44; principalmente con minoxidil oral a dosis de 0&#44;5-1<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#237;a&#44; y&#44; en menor medida&#44; con espironolactona<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">1&#44;2</span></a>&#46; El tiempo transcurrido hasta la mejor&#237;a vari&#243; entre los 6 meses y los 2 a&#241;os&#44; encontr&#225;ndose una mejor&#237;a a los 6 meses de un 20&#44;2 a un 27&#44;5&#37; en la escala de Sinclair<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">1&#44;2</span></a> &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">tabla 1</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0020" class="elsevierStylePara elsevierViewall">Dada su actividad antiandrog&#233;nica&#44; algunos estudios sugieren que su empleo a una dosis media de 14&#44;4<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#237;a concomitante con minoxidil oral a una dosis media de 1&#44;5<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#237;a durante m&#225;s de 3 meses&#44; podr&#237;a reducir la hipertricosis secundaria a este&#44; lo que permitir&#237;a obtener una mejor tolerancia a dosis altas de minoxidil y&#44; as&#237;&#44; optimizar el tratamiento de la AAPF<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">3</span></a>&#46;</p><p id="par0025" class="elsevierStylePara elsevierViewall">Debido a su papel sobre la miniaturizaci&#243;n del fol&#237;culo&#44; y teniendo en cuenta el efecto anterior&#44; se utiliz&#243; con &#233;xito en una paciente con alopecia central centr&#237;fuga con una dosis de 10<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#237;a&#44; en combinaci&#243;n con 0&#44;45<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#237;a de minoxidil oral y un corticoide t&#243;pico<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">4</span></a>&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">En los estudios publicados ha presentado un buen perfil de seguridad y tolerabilidad<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">1&#8211;3</span></a>&#46; El efecto secundario m&#225;s referido fue la hepatotoxicidad&#44; encontr&#225;ndose hipertransaminasemia en el 2&#44;9-12&#44;5&#37;&#44; en todos los casos con un valor inferior a 3 veces el l&#237;mite superior de normalidad<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">5</span></a>&#46; Este efecto ser&#237;a dosis dependiente&#44; mejorando la mayor&#237;a de los casos de forma espont&#225;nea o tras disminuir la dosis de bicalutamida&#44; sin requerir su suspensi&#243;n<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a>&#46; Otros efectos indeseables menos frecuentes fueron alteraciones gastrointestinales&#44; edema de miembros&#44; mastalgia o migra&#241;a&#44; entre otros &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">tabla 1</a>&#41;<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">1&#8211;3</span></a>&#46;</p><p id="par0035" class="elsevierStylePara elsevierViewall">La bicalutamida est&#225; contraindicada en mujeres embarazadas y se recomienda administrarla con precauci&#243;n en mujeres con una historia personal o familiar de tumores hormono-dependientes<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">5</span></a>&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">Dada la evidencia actual&#44; se ha propuesto realizar previo a su inicio una anal&#237;tica sangu&#237;nea que incluya hemograma&#44; creatinina&#44; enzimas hep&#225;ticas&#44; perfil lip&#237;dico y tiempo de protrombina&#46; Esta se debe repetir durante el seguimiento cada 3-6 meses<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">2&#44;5</span></a>&#46;</p><p id="par0045" class="elsevierStylePara elsevierViewall">En los &#250;ltimos a&#241;os&#44; los avances en el conocimiento de la bicalutamida han permitido valorarla como una importante alternativa en el tratamiento de AAPF&#44; sobre todo en las pacientes premenop&#225;usicas con otros rasgos de hiperandrogenismo como acn&#233;&#44; hirsutismo o seborrea<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">1</span></a>&#46; Aunque se requiere una mayor evidencia que corrobore su eficacia&#44; seguridad y estandaricen su posolog&#237;a y seguimiento&#44; parece que su uso a una dosis de 10-50<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#237;a es eficaz y seguro en monoterapia o en combinaci&#243;n con otros f&#225;rmacos&#46;</p></span>"
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:1 [
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec1702476"
          "palabras" => array:4 [
            0 => "Alopecia androgen&#233;tica"
            1 => "Bicalutamida"
            2 => "Minoxidil"
            3 => "Hipertricosis"
          ]
        ]
      ]
    ]
    "multimedia" => array:1 [
      0 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Tabla 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Autor&#237;a del estudio&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Tipo de estudio&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Patolog&#237;a tratada&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N&#46;<span class="elsevierStyleSup">o</span> pacientes tratados&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Posolog&#237;a&#40;mg&#47;d&#237;a&#41;&#91;&#37; pacientes tratados&#93;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">F&#225;rmacos concomitantes&#40;&#37; pacientes tratados&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Duraci&#243;n del tratamiento&#40;meses&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Tiempo inicial de mejor&#237;a medido&#40;meses&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Resultados a los 6 meses&#40;reducci&#243;n escala de Sinclair&#44; &#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Efectos secundarios&#40;&#37; pacientes afectos&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N&#46;<span class="elsevierStyleSup">o</span> abandonos terap&#233;uticos por efectos secundarios&#40;&#37; de abandonos&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ismail et al&#46;<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Serie de casos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">AAPF&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">316&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-10 &#91;69&#44;6&#37;&#93;-12&#44;5 &#91;2&#44;5&#37;&#93;-20 &#91;25&#37;&#93;-25 &#91;1&#37;&#125;-30 &#91;1&#46;6&#37;&#93;-50 &#91;0&#44;3&#37;&#93;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-Minoxidil oral<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> &#40;97&#44;4&#37;&#41;-Espironolactona<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a>&#40;54&#44;4&#37;&#41;-Monoterapia &#40;1&#44;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2-69&#40;6&#44;21 de media&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">20&#44;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-Hipertransaminasemia &#40;2&#44;9&#37;&#41;-Edema en miembros &#40;2&#44;5&#37;&#41;-Alteraciones gastrointestinales &#40;1&#44;9&#37;&#41;-En<span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>1&#37; de los casos&#44; respectivamente&#58; mastalgia&#44; erupci&#243;n acneiforme&#44; astenia&#44; mialgias&#44; disminuci&#243;n de la libido&#44; alteraciones menstruales&#44; cambios de humor&#44; palpitaciones y disnea&#44; fotosensibilidad&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">13&#40;4&#44;1&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Fern&#225;ndez-Nieto et al&#46;<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">1</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Serie de casos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">AAPF&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">44&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-25 &#91;34&#44;1&#37;&#93;-50 &#91;65&#44;9&#37;&#93;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-Minoxidil oral 0&#44;5-1<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#237;a &#40;75&#44;0&#37;&#41;-Dutasteride oral 0&#44;5<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#237;a &#40;15&#44;9&#37;&#41;-Dutasteride en mesoterapia &#40;13&#44;6&#37;&#41;- Minoxidil t&#243;pico 5&#37; &#40;11&#44;4&#37;&#41;-Monoterapia &#40;6&#44;8&#37;&#41;-Finasteride oral 2&#44;5mg&#47;d&#237;a &#40;2&#44;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2-24&#40;10&#44;5 de media&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">27&#44;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-Hipertransaminasemia &#40;11&#44;4&#37;&#41;-Efluvio &#40;6&#44;8&#37;&#41;-Alteraciones menstruales &#40;4&#44;5&#37;&#41;-Migra&#241;a &#40;2&#44;2&#37;&#41;-Hiperplasia endometrial &#40;2&#44;2&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Moussa et al&#46;<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">3</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Serie de casos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hipertricosis secundaria a minoxidil en AAPF&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">35&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-10 &#91;57&#37;&#93;-20 &#91;40&#37;&#93;-25 &#91;3&#37;&#93;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-Minoxidil oral 0&#44;25-10<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#237;a &#91;dosis media de 1&#44;5<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#237;a&#93;&#40;100&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">28&#44;9&#40;25&#44;92 de media&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#44;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">19&#44;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-Hipertransaminasemia &#40;6&#37;&#41;-Disestesia del cuero cabelludo &#40;3&#37;&#41;-Migra&#241;a &#40;3&#37;&#41;-Edema periocular &#40;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#40;5&#44;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Lobon et al&#46;<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">4</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Caso cl&#237;nico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Alopecia central centr&#237;fuga&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">10&#44; con incremento a 20 &#91;100&#37;&#93;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-Minoxidil oral 0&#44;45<span class="elsevierStyleHsp" style=""></span>mg&#47;d&#237;a y dipropionato de clobetasol 0&#44;05&#37; t&#243;pico&#40;100&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">-&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3295016.png"
              ]
            ]
          ]
          "notaPie" => array:2 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Dosis de minoxidil oral no especificada&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "b"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Dosis de espironolactona no especificada&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Resumen de la literatura actual acerca del empleo de bicalutamida en tricolog&#237;a</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliograf&#237;a"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:5 [
            0 => array:3 [
              "identificador" => "bib0030"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bicalutamide&#58; A potential new oral antiandrogenic drug for female pattern hair loss"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "D&#46; Fernandez-Nieto"
                            1 => "D&#46; Saceda-Corralo"
                            2 => "J&#46; Jimenez-Cauhe"
                            3 => "O&#46;M&#46; Moreno-Arrones"
                            4 => "R&#46; Rodrigues-Barata"
                            5 => "A&#46; Hermosa-Gelbard"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2020.04.0544"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol &#91;Internet&#93;&#46;"
                        "fecha" => "2020"
                        "volumen" => "83"
                        "paginaInicial" => "e355"
                        "paginaFinal" => "e356"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32320770"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0035"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Safety of oral bicalutamide in female pattern hair loss&#58; A retrospective review of 316 patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "F&#46;F&#46; Ismail"
                            1 => "N&#46; Meah"
                            2 => "L&#46; Trindade de Carvalho"
                            3 => "B&#46; Bhoyrul"
                            4 => "D&#46; Wall"
                            5 => "R&#46; Sinclair"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2020.03.034"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol &#91;Internet&#93;&#46;"
                        "fecha" => "2020"
                        "volumen" => "83"
                        "paginaInicial" => "1478"
                        "paginaFinal" => "1479"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32213304"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bicalutamide improves minoxidil-induced hypertrichosis in female pattern hair loss&#58; A retrospective review of 35 patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "A&#46; Moussa"
                            1 => "A&#46; Kazmi"
                            2 => "L&#46; Bokhari"
                            3 => "R&#46;D&#46; Sinclair"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2021.10.0485"
                      "Revista" => array:2 [
                        "tituloSerie" => "J Am Acad Dermatol &#91;Internet&#93;&#46;"
                        "fecha" => "2021"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0045"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Significant hair regrowth in a Middle Eastern woman with central centrifugal cicatricial alopecia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "K&#46; Lobon"
                            1 => "J&#46; Pinczewski"
                            2 => "B&#46; Bhoyrul"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/ced.14822"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Exp Dermatol &#91;Internet&#93;&#46;"
                        "fecha" => "2022"
                        "volumen" => "47"
                        "paginaInicial" => "136"
                        "paginaFinal" => "138"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34192377"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bicalutamide and the new perspectives for female pattern hair loss treatment&#58; What dermatologists should know"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46;M&#46; Carvalho"
                            1 => "L&#46;D&#46;N&#46; Santos"
                            2 => "P&#46;M&#46; Ramos"
                            3 => "C&#46;J&#46; Machado"
                            4 => "P&#46; Acioly"
                            5 => "S&#46;C&#46; Frattini"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jocd.14773"
                      "Revista" => array:3 [
                        "tituloSerie" => "J Cosmet Dermatol &#91;Internet&#93;&#46;"
                        "fecha" => "2022"
                        "itemHostRev" => array:3 [
                          "pii" => "S0002939420302890"
                          "estado" => "S300"
                          "issn" => "00029394"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "es"
  "url" => "/00017310/0000011400000009/v1_202310020456/S0001731023005057/v1_202310020456/es/main.assets"
  "Apartado" => array:4 [
    "identificador" => "34907"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Foro de Residentes"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/00017310/0000011400000009/v1_202310020456/S0001731023005057/v1_202310020456/es/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023005057?idApp=UINPBA000044"
]
Información del artículo
ISSN: 00017310
Idioma original: Español
Datos actualizados diariamente
año/Mes Html Pdf Total
2024 Noviembre 96 22 118
2024 Octubre 1219 125 1344
2024 Septiembre 1155 131 1286
2024 Agosto 1056 146 1202
2024 Julio 1078 115 1193
2024 Junio 803 107 910
2024 Mayo 849 121 970
2024 Abril 596 101 697
2024 Marzo 577 110 687
2024 Febrero 488 89 577
2024 Enero 617 98 715
2023 Diciembre 564 81 645
2023 Noviembre 567 121 688
2023 Octubre 694 162 856
2023 Septiembre 351 72 423
2023 Agosto 273 75 348
2023 Julio 264 141 405
2023 Junio 41 114 155
Mostrar todo

Siga este enlace para acceder al texto completo del artículo

Idiomas
Actas Dermo-Sifiliográficas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?